

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	Address: .....	.....
.....	.....	.....
Fax Number: .....	.....	Fax Number: .....

**Risdiplam**

**Initial application — spinal muscular atrophy (SMA)**

Applications from any relevant practitioner. Approvals valid for 12 months.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/>	Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation
<b>and</b>	
<input type="checkbox"/>	Patient is 18 years of age or under
<b>and</b>	
<input type="checkbox"/>	Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age
<b>or</b>	
<input type="checkbox"/>	Patient is pre-symptomatic
<b>and</b>	
<input type="checkbox"/>	Patient has three or less copies of SMN2

**Renewal — spinal muscular atrophy (SMA)**

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 12 months.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/>	There has been demonstrated maintenance of motor milestone function since treatment initiation
<b>and</b>	
<input type="checkbox"/>	Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam
<b>and</b>	
<input type="checkbox"/>	Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)